SYGNIS AG plans to acquire profitable proteomics player Expedeon Holdings Ltd.

SYGNIS AG / Key word(s): Mergers & Acquisitions

09.05.2016 09:00

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Ad hoc announcement according to § 15 WpHG


SYGNIS AG plans to acquire profitable proteomics player
Expedeon Holdings Ltd.

- Acquisition provides well-established direct sales forces in the U.S.
and Europe and broadens product portfolio

- Combined 2016 pro-forma revenues to exceed EUR 5 million

- Planned capital increase by way of a rights offering of up to 20.5
million shares

- New shares not subscribed will be offered to Expedeon shareholders as
contribution in kind in exchange for Expedeon shares

- Expected proceeds of up to EUR 5 million to cover additional cash
payment to Expedeon shareholders and transaction-related expenses

- The Company will host a conference call today at 14:00 Central European
Time (CET)

Madrid, Spain and Heidelberg, Germany, 9 May, 2016 - SYGNIS AG (Frankfurt:
LIO1; ISIN: DE000A1RFM03; Prime Standard) today resolved, with the approval
of the Supervisory Board, to acquire Expedeon Holdings Ltd., a privately
held UK proteomics company with sales offices in the U.S., UK and
Singapore. Expedeon develops, manufactures and commercializes proteomics
reagents and tools, marketed worldwide by Expedeon's direct sales force and
via distributors.

To finance the transaction, the Management Board of SYGNIS AG has resolved,
with the approval of the Supervisory Board, to increase the Company's share
capital by up to EUR 20,538,089.00 from EUR 16,803,891.00 to EUR
37,341,980.00 by issuing up to 20,538,089 shares by way of a rights

New shares not subscribed in the rights offering will be offered to
Expedeon shareholders as contribution in kind against Expedeon shares.
SYGNIS intends to acquire Expedeon by issuing approximately 80% of the new
shares against contributions in kind (Expedeon shares).

Any new shares not subscribed by SYGNIS or Expedeon shareholders will be
offered to select qualified investors in a private placement. Expected
proceeds from the capital increase of up to EUR 5 million will be used for
transaction-related expenses, including EUR 1.7 million cash payments to
Expedeon shareholders, one-off integration costs and financing working
capital. The transaction is subject to the approval by the Annual General
Meeting on 20 June 2016.

SYGNIS will host a conference call (conducted in English) today at 14:00
Central European Time (CET), hosted by Pilar de la Huerta, CEO and CFO of
SYGNIS, to discuss the planned acquisition of Expedeon.

Conference call details:

Time: 9 May 2016, 14:00 Central European Time (CET)

Interested parties can access the conference call via the following
telephone numbers:

* From Germany: +49 (0) 69 7104 45598
* From Spain: +34 91 787 0777
* From the U.S.: +1 646 843 4608
* From the UK and other countries: +44 (0) 20 3003 2666

When prompted, please provide the password, "SYGNIS".

The conference call, which is also being webcast, will be accompanied by a
slide presentation which can be accessed during the call at:

Please dial in 5 minutes before the beginning of the event.

A conference call recording will be available in the "Investors" section of
the Company's website at following the live call.

XXX end of ad hoc announcement XXX

For further information please contact:

Pilar de la Huerta Raimund Gabriel
CEO/CFO Managing Partner
Phone: +34 91 192 36 50 Phone: +49 89 210228 30
Email: Email:


SYGNIS, headquartered in Germany and Spain, specializes in the development
and commercialization of innovative products for DNA amplification and
sequencing. Based on its proprietary technologies, SYGNIS has developed a
commercial product portfolio addressing key challenges in the fast-growing
fields of molecular biology and next-generation sequencing applications.
Key products include the TruePrime(TM) product line and SensiPhi(R),
licensed to a leading industry partner, for whole genome DNA amplification
and sequencing, as well as the SunScript(TM) Reverse Transcriptase product
family to convert genetic information from RNA molecules back to DNA.
SYGNIS AG is listed on the German Stock Exchange in the Prime Standard
segment (Ticker: LIO1; ISIN: DE000A1RFM03).

About Expedeon Holdings Ltd.:

Expedeon Holdings Ltd. is privately held proteomics tools and reagents
company headquartered in the UK. Expedeon is focused on providing high
quality, simple and rapid solutions for protein research including
RunBlue(R) gels for electrophoresis, the VersaWave spectrophotometer for
quantitation or NVoy kits for refolding proteins to name just a few.
Expedeon manufactures and sells a wide range of innovative, proprietary
products through a direct sales force as well as well-established
distribution channels. The company has manufacturing facilities in San
Diego, California, USA and a representative office in Singapore.

### This document is not a securities prospectus and the information
contained herein does not constitute an offer to sell or a solicitation of
an offer to purchase any securities of SYGNIS AG in the Federal Republic of
Germany nor under any other jurisdiction, in particular not where such kind
of offer or solicitation is prohibited or lacks the required permission.
Potential investors in securities of SYGNIS AG are asked to familiarize
themselves with and to observe the respective restrictions.

A decision to invest in the securities of SYGNIS AG should only be made on
the basis of the securities prospectus detailing the public offering of
securities of SYGNIS AG in the Federal Republic of Germany, which, subject
to the approval of the German Federal Financial Supervisory Authority
(BaFin) is anticipated to be published under

The information in this document may not be disseminated outside the
Federal Republic of Germany in particular not in the United States, to U.S.
Persons (as defined in regulation S of the U.S. Securities Act of 1933) or
to publications with a general circulation in the United States with the
exception of a such disclosures or announcements outside the Federal
Republic of Germany which have to be made under the respective mandatory
law. Any person who fails to comply with these restrictions may violate the
security laws of certain jurisdictions, in particular of the United States.
Securities in SYGNIS AG are not publicly offered outside the Federal
Republic of Germany.

Some statements included in this press release, relating neither to proven
financial results nor other historical data, should be viewed as
forward-looking, i.e. not definite. Such statements are mainly predictions
of future results, trends, plans or goals. These statements should not be
considered to be total guarantees since given their very nature they are
subject to known and unknown risks and imponderability and can be affected
by other factors as a consequence of which the actual results, plans and
goals of SYGNIS AG may deviate greatly from the established conclusions or
implied predictions contained in such statements. SYGNIS does not undertake
to publicly update or revise these statements in the light of new
information or future results or for any other reason. ###

09.05.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at and


Language: English
Company: SYGNIS AG
Waldhofer Str. 104
69123 Heidelberg
Phone: +49 (0) 6221 3540 125
Fax: +49 (0) 6221 3540 127
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,

End of Announcement DGAP News-Service